Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: A survey study

Journal of Hospital Medicine

Volumn 11, Issue 1, 2016, Pages 21-26

  Zilberberg, Marya D ^a,b   Kollef, Marin H ^c   Shorr, Andrew F ^d  

^a EviMed Research Group LLC   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM; COLISTIN; COTRIMOXAZOLE; DORIPENEM; DOXYCYCLINE; IMIPENEM; MEROPENEM; MINOCYCLINE; POLYMYXIN B; SULTAMICILLIN; TOBRAMYCIN; AMPICILLIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; SULBACTAM;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; CONTROLLED STUDY; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; NURSING HOME; OUTPATIENT DEPARTMENT; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TREND STUDY; UNITED STATES; WARD; ACINETOBACTER INFECTIONS; BACTEREMIA; CROSS INFECTION; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PROCEDURES; QUESTIONNAIRE; RESPIRATORY TRACT INFECTIONS;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AMPICILLIN; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; SULBACTAM; SURVEYS AND QUESTIONNAIRES; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; UNITED STATES;

EID: 84953213084     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.2477     Document Type: Article

References (31)

1. National Nosocomial Infections Surveillance (NNIS) System Report. Am J Infect Control. 2004;32:470-485.
2. Obritsch MD, Fish DN, MacLaren R, Jung R. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother. 2004;48:4606-4610.
3. Micek ST, Kollef KE, Reichley RM, et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568-3573.
4. Iregui M, Ward S, Sherman G, et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262-268.
5. Alvarez-Lerma F; ICU-Acquired Pneumonia Study Group. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med. 1996;22:387-394.
6. Zilberberg MD, Shorr AF, Micek MT, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with HCAP: a single center experience. Chest. 2008:134:963-968.
7. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med. 2008;36:296-327.
8. Shorr AF, Micek ST, Welch EC, Doherty JA, Reichley RM, Kollef MH. Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay. Crit Care Med. 2011;39:46-51.
9. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462-474.
10. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf#page=59. Accessed December 29, 2014.
11. Sievert DM, Ricks P, Edwards JR, et al.; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013;34:1-14.
12. Zilberberg MD, Shorr AF, Micek ST, Vazquez-Guillamet C, Kollef MH. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care. 2014;18(6):596.
13. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2007;51:3471-3484.
14. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Predictors of hospital mortality among septic ICU patients with Acinetobacter spp. bacteremia: a cohort study. BMC Infect Dis. 2014;14:572.
15. Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis. 2010;51:79-84.
16. Hoffmann MS, Eber MR, Laxminarayan R. Increasing resistance of Acinetobacter species to imipenem in United States hospitals, 1999-2006. Infect Control Hosp Epidemiol. 2010;31:196-197.
17. Braykov NP, Eber MR, Klein EY, Morgan DJ, Laxminarayan R. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of Klebsiella pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol. 2013;34:259-268.
18. Sahm DF, Marsilio MK, Piazza G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis. 1999;29:259-263.
19. Klein E, Smith DL, Laxminarayan R. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis. 2009;15:1925-1930.
20. Jones ME, Draghi DC, Karlowsky JA, Sahm DF, Bradley JS. Prevalence of antimicrobial resistance in bacteria isolated from central nervous system specimens as reported by U.S. hospital laboratories from 2000 to 2002. Ann Clin Microbiol Antimicrob. 2004;3:3.
21. Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute; 2012.
22. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-281.
23. CDDEP: The Center for Disease Dynamics, Economics and Policy. Resistance map: Acinetobacter baumannii overview. Available at: http://www.cddep.org/projects/resistance:map/acinetobacter_baumannii_overview. Accessed January 16, 2015.
24. Thom KA, Maragakis LL, Richards K, et al.; Maryland MDRO Prevention Collaborative. Assessing the burden of Acinetobacter baumannii in Maryland: a statewide cross-sectional period prevalence survey. Infect Control Hosp Epidemiol. 2012;33:883-888.
25. Mortensen E, Trivedi KK, Rosenberg J, et al. Multidrug-resistant Acinetobacter baumannii infection, colonization, and transmission related to a long-term care facility providing subacute care. Infect Control Hosp Epidemiol. 2014;35:406-411.
26. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest. 2001;120:1072-1077.
27. Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as distinct clinical syndrome. Chest. 2006;129:102-109.
28. Salas Coronas, J, Cabezas Fernandez T, Alvarez-Ossorio Garcia de Soria R, Diez Garcia F. Community-acquired Acinetobacter baumannii pneumonia. Rev Clin Esp. 2003;203:284-286.
29. Wu CL, Ku SC, Yang KY, et al. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J Formos Med Assoc. 2013;112:31-40.
30. Restrepo MI, Velez MI, Serna G, Anzueto A, Mortensen EM. Antimicrobial resistance in Hispanic patients hospitalized in San Antonio, TX with community-acquired pneumonia. Hosp Pract (1995). 2010;38:108-113.
31. Frieden T. Centers for Disease Control and Prevention. CDC director blog. The end of antibiotics. Can we come back from the brink? Available at: http://blogs.cdc.gov/cdcdirector/2014/05/05/the-end-of-antibiotics-can-we-come-back-from-the-brink/. Published May 5, 2014. Accessed January 16, 2015.